Try our Advanced Search for more refined results
Health
-
January 15, 2026
Insurer Owes $24.5M For Burn Case, Medical Spa Trustee Says
A trustee for the bankruptcy estate of a former medical spa owner alleged that Aspen Specialty Insurance Co. breached its duty to defend the woman in litigation over a client's burn injury, forcing her to face a $24.5 million default judgment.
-
January 15, 2026
Fla. Eye Clinics To Pay $6M Over False Medical Billing Claims
Five Florida ophthalmology clinics have reached settlements with the government over allegations that they filed false claims to Medicare and Medicaid, agreeing to collectively pay nearly $6 million to resolve accusations that the clinics billed the federal healthcare programs for medically unnecessary eye procedures.
-
January 15, 2026
Rite Aid Trusts Can Access Health Data To Pursue Tort Claims
A New Jersey bankruptcy judge said Thursday he will allow trusts set up under Rite Aid's first Chapter 11 plan to examine personal health data to support their effort to litigate tort and insurance claims, overruling the new Rite Aid debtor's objection.
-
January 15, 2026
Crowell Lands Buchalter Practice Group Co-Chair In Calif.
Crowell & Moring LLP announced Thursday that it has added the former co-chair of Buchalter PC's white collar and government investigations practice to bolster its capacity to handle healthcare fraud and other cases.
-
January 15, 2026
Rehab Center's Suit Against Atty Can Proceed, 6th Circ. Says
An Ohio attorney accused of mishandling the sale of a substance abuse treatment center in West Virginia is facing revived malpractice claims after the Sixth Circuit reversed a federal district court ruling that found the client waited too long to file suit against the lawyer.
-
January 15, 2026
Carlyle Among Bidders For Lukoil Assets, Plus More Rumors
Private equity giant Carlyle is among a group of bidders reportedly looking to grab hold of $22 billion worth of Russia's Lukoil assets; Canadian oil and gas company Canadian Natural Resources is looking to acquire Tourmaline Oil Corp.'s $1 billion portfolio of natural gas properties; and Nvidia rival Cerebras eyes a $22 billion valuation after a planned $1 billion funding round.
-
January 15, 2026
Ambulance Co. Will Pay $225K To Settle OT Suit
An Illinois ambulance services company will pay $225,000 to end a suit alleging it violated wage law by only paying employees overtime when they worked more than 80 hours in a two-week period, according to a federal judge's order approving the deal.
-
January 15, 2026
3 Firms Advise On Boston Scientific's $14.5B Penumbra Deal
Allen Overy Shearman Sterling and Arnold & Porter are advising Boston Scientific Corp. on an agreement announced Thursday for the global medical technology company to purchase Davis Polk-advised Penumbra Inc. at a $14.5 billion enterprise value.
-
January 14, 2026
Call Vendors Skirt Wiretap Suit Over AI Transcription Tool
An Illinois federal judge has released dental support organization Heartland Dental LLC and its contractor from a proposed class action accusing them of illegally using an artificial intelligence-powered note-taking tool to record and analyze patient calls, finding that they couldn't be held liable because their alleged electronic interceptions were made for legitimate business purposes.
-
January 14, 2026
Dover Launches RICO Suit Over Skyrocketing Insulin Prices
Manufacturing conglomerate Dover Corp. hit insulin manufacturers including Eli Lilly and Novo Nordisk and several pharmacy benefit managers with civil racketeering claims in Illinois federal court, accusing them of participating in an illegal scheme that allowed prices to rise dramatically in exchange for preferential treatment on the benefit managers' formularies.
-
January 14, 2026
Pharmacy Wields Antitrust Law In Challenge To GLP-1 Giants
Eli Lilly & Co. and Novo Nordisk are using their dominant positions in the market for weight loss and diabetes medications to squash potential competitors, including through unlawful exclusivity agreements with telehealth providers, a compounding pharmacy alleged Wednesday in what it calls a landmark antitrust lawsuit.
-
January 14, 2026
Kaiser Entities Settle Medicare Fraud Claims For $556M
Five Kaiser Permanente affiliates agreed to a $556 million settlement resolving allegations they defrauded the government by submitting invalid medical diagnoses for Medicare Advantage Plan enrollees, the U.S. Department of Justice announced Wednesday.
-
January 14, 2026
Tort Report: Los Angeles Tops Annual 'Judicial Hellhole' List
Los Angeles' designation by a tort reform group as a top "judicial hellhole," and the latest in a suit over a Kentucky judge shot to death in his own chambers lead Law360's Tort Report, which compiles recent personal injury and medical malpractice news that may have flown under the radar.
-
January 14, 2026
6th Circ. Skips Rethink, But Still Spars Over Indirect Buyer Bar
A decision by the full Sixth Circuit not to rehear a lawsuit over an alleged allergy testing and treatment provider boycott has turned into an internal dustup about the limits of who can seek damages under federal antitrust law, with one judge calling for U.S. Supreme Court intervention.
-
January 14, 2026
Feds Sue Calif. Over Ban On Drilling Near Schools, Homes
The U.S. government sued California on Wednesday over its law banning fossil fuel development activities within 3,200 feet of homes, schools and other sensitive areas, saying the state law is preempted by federal law since it infringes on the U.S. government's authority to manage federal lands and mineral resources.
-
January 14, 2026
Mich. Panel Revives Man's Goose Attack Injury Claim
A Michigan state appeals court revived premises liability claims against a hospital accused of not warning a contractor about a known risk of a dangerous goose frequenting the area.
-
January 14, 2026
State Dept. Pauses Immigrant Visas For 75 Countries
The U.S. Department of State said Wednesday that it is indefinitely pausing immigrant visas for people from 75 countries who the agency said are likely to rely on government support and stress the public purse.
-
January 14, 2026
NJ Judge Orders Mediation In Merck-Cencora Indemnity Fight
Cencora Inc. can't derail a Merck third-party complaint arguing a prior settlement between the parties requires the drug wholesaler to indemnify Merck in antitrust litigation by Humana, a New Jersey federal court ruled Wednesday, ordering the parties to go to mediation over the dispute.
-
January 14, 2026
Biotech Co. CytoDyn In Talks To End Investor Class Action
A federal judge has given the green light for biotech company CytoDyn Inc. and its former leadership to move forward with a potential settlement of a proposed class action that accused the company of misleading shareholders over the alleged approval of its COVID-19 and HIV drug.
-
January 14, 2026
'The Work Has Changed': How White-Collar Attys Are Coping
The Trump administration's dramatic policy enforcement changes over the past year, along with turmoil and turnover at the U.S. Department of Justice, has tilted the white-collar world on its axis, forcing lawyers and firms to abruptly shift focus and expand their practices, sometimes beyond traditional white-collar criminal defense matters.
-
January 14, 2026
Vizient Beats Spurned Medical Tape Supplier At 5th Circ.
A Fifth Circuit panel refused to revive an antitrust suit accusing medical supplies group purchasing giant Vizient of locking in hospital customers, agreeing with a district court that a spurned would-be supplier failed at the threshold question of showing a market in which Vizient could be dominant.
-
January 14, 2026
NJ High Court Says Inmate Record Ban Violates Constitution
The New Jersey Supreme Court said in a reversal Wednesday that the state's parole board cannot bar the disclosure to inmates of medical, psychiatric and psychological records used to determine their parole eligibility, finding that withholding this information from them is unconstitutional and against state law.
-
January 14, 2026
Wholesaler Admits To $2.5M Opioid Diversion Scheme
A Miami-based pharmaceutical wholesaler has signed on to a two-year deferred prosecution agreement with federal prosecutors over a charge that it knowingly diverted opioids to "pill mill" pharmacies, bringing in more than $2.5 million.
-
January 14, 2026
GOP Senators Say Patients Must See Docs For Abortion Meds
Republicans on a Senate health panel Wednesday called for the U.S. Food and Drug Administration to reinstate a requirement that pregnant women seeking an abortion via medication must have the drug administered in a doctor's office, not through telehealth or remotely.
-
January 13, 2026
Teva Can't Visit 11th Circ. Ahead Of 1st Paragard Bellwether
A Georgia federal judge refused to delay the first bellwether trial in the Paragard IUD MDL, rejecting Teva's request for an immediate Eleventh Circuit appeal regarding a ruling allowing plaintiffs to use injury data that the drugmaker located only after implantation.
Expert Analysis
-
Preparing For Congressional Investigations In A Midterm Year
2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.
-
A Meaningful Shift In FDA's Biosimilarity Analysis
The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.
-
Employment Immigration Trends And Challenges For 2026
U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.
-
Top 5 Antitrust Issues For In-House Counsel To Watch In 2026
With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.
-
4 Developments That Defined The 2025 Ethics Landscape
The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.
-
Navigating AI In The Legal Industry
As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.
-
How Fractional GCs Can Manage Risks Of Engagement
As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.
-
Health, Legal Employers Face Unique Online Speech Hurdles
Employers in the legal and healthcare industries must consider distinctive ethical obligations and professional requirements when disciplining employees for social media posts, while anticipating an area of the law in flux as courts seek to balance speech rights and the workplace function, say attorneys at FordHarrison.
-
Reviewing 2025's Most Pertinent Wiretap Developments
2025 was a remarkable year in the world of web tracking wiretapping litigation, not only for the increased caseload but also because of numerous developing theories of liability, with disputes expected to continue unabated in 2026, say attorneys at Squire Patton.
-
2025 Legal Milestones That Will Shape Psychedelics Sector
As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.
-
Series
Nature Photography Makes Me A Better Lawyer
Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.
-
2025 State AI Laws Expand Liability, Raise Insurance Risks
As 2025 nears its end, claims professionals should be aware of trends in state legislation addressing artificial intelligence use, as insurance claims based on some of these liability-expanding statutes are a certainty, say attorneys at Wiley.
-
Series
Law School's Missed Lessons: Practical Problem Solving
Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.
-
Intellectual Property Challenges In AI-Driven Drug Discovery
Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.
-
Learning From 2025 FCA Trends Targeting PE In Healthcare
False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.